Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Summary

The purpose of the study is to determine the overall response rate of single agent TRC105 and the combination of TRC105 and bevacizumab in patients with refractory GTN (including choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT)). Up to 30 patients will be treated.

Timeline

Start

2016-03

Primary completion

2018-04

Completion

2018-11

Outcome

Outcome not reported

Stopped: “Rare tumor type, patients eligible via expanded access.”

Drugs

Indications